Chinese trade negotiators suddenly canceled a visit to meet U.S. farmers after they wrapped up trade talks in Washington this week.Marketsread more
Blackstone Executive Vice Chairman Tony James says he's less optimistic now than before that the U.S.-China trade war could be resolved, but even a smaller deal could help...World Economyread more
The Pentagon will deploy U.S. forces to the Middle East on the heels of the attack on Saudi Arabian oil facilities, United States Secretary of Defense Mark Esper announced...Defenseread more
President Trump also said he is "not looking for a partial deal" with Beijing, moving away from his suggestion last week that he would consider an "interim deal."Politicsread more
Progress on trade talks will determine how far market will move above new highs.Trader Talk with Bob Pisaniread more
"Sure, the trade war's taking its toll on business ... it's just not taking its toll where it was supposed to," Jim Cramer says.Mad Money with Jim Cramerread more
Joe Biden called on President Donald Trump Friday to release the transcript of a call with a foreign leader that is the subject of a whistleblower complaint. Biden described...Politicsread more
For investors taking a breather from the chaos in August, buckle up as the market is about go crazy again, Goldman Sachs warned.Marketsread more
Palantir Technologies is targeting a valuation of at least $26 billion in a private fundraising round, the first for the Peter Thiel-backed data analytics startup in four...Wall Streetread more
Michael Pack, a conservative filmmaker linked to Steve Bannon, saw at least $1.6 million in donations from his nonprofit sent into the coffers of his independent production...Politicsread more
The New England Patriots released Antonio Brown just 11 days after signing the wide receiver. The NFL Super Bowl champion team initially had kept him in the face of a rape...Sportsread more
Lundbeck said that it saw weak efficacy for its drug idalopirdine, a symptomatic treatment for Alzheimer's disease. Axovant's lead Alzheimer's product uses the same mechanism as Lundbeck's.
The company is disappointed by the outcome of the study, Anders Gersel Pedersen, executive vice president and chief scientific officer at Lundbeck, said in a statement.
"The phase II data were very encouraging but unfortunately, these data failed to replicate those findings," he said.
Axovant shares were briefly halted for volatility in intraday trade on Thursday. They closed about 12 percent lower.
A spokesman for Axovant told CNBC that the results from Lundbeck's study were expected and that "weak efficacy" in their trial "is not surprising to" Axovant.
"By contrast, the objective of our Phase 3 1150-patient MINDSET study is to confirm the results of a 684-patient Phase 2 study that demonstrated statistically significant improvements on cognition and function," he said. "Based on today's news, and subject to FDA approval, intepirdine could now be the first drug of its class to be approved for the treatment of mild-to-moderate Alzheimer's disease – potentially becoming the first approved treatment for this disease since 2003."
Copenhagen-listed shares of Lundbeck closed up about 0.89 percent in European trade. The stock is up 15 percent this year, while Axovant shares have fallen 20 percent in the same period.